|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study I
The objective of this study is to evaluate the efficacy and safety of TDS-943 (topical diclofenac spray) compared to oral celecoxib and placebo in subjects with osteoarthritis of the knee. The main hypotheses are that TDS-943 will be better than placebo and no worse than celecoxib.
The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II
The objective of this study is to evaluate the efficacy and safety of TDS-943 (topical diclofenac spray) compared to oral celecoxib and placebo in subjects with osteoarthritis of the knee. The main hypotheses are that TDS-943 will be better than placebo and no worse than celecoxib.
100 项与 MIKA Pharma GmbH 相关的临床结果
0 项与 MIKA Pharma GmbH 相关的专利(医药)
100 项与 MIKA Pharma GmbH 相关的药物交易
100 项与 MIKA Pharma GmbH 相关的转化医学